PSS15 THE COST-EFFECTIVENESS OF RANIBIZUMAB (LUCENTIS) IN TREATING PATIENTS WITH PREDOMINANTLY CLASSIC, MINIMALLY CLASSIC, AND OCCULT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (AMD)
Abstract
Authors
A Turpcu JW Hay
A Turpcu JW Hay
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now